脾切除后PRRT长期血液毒性多中心配对分析
该多中心回顾性配对研究纳入2009至2022年接受177Lu-DOTATATE PRRT的68例转移性神经内分泌肿瘤患者,比较脾切除组(34例)与非脾切除组的血液学毒性。结果显示脾切除患者24个月白细胞下降12.8% vs 47.2%(P<0.001),白细胞减少仅2例 vs 20例(P<0.001),提示脾切除可减轻PRRT相关白细胞减少并改善血液学耐受性。
要点
- 脾切除患者PRRT后24个月白细胞下降12.8%,显著低于非脾切除的47.2%(P<0.001)。
- 脾切除组白细胞减少仅2例,对照组20例(P<0.001),淋巴细胞下降也更轻。
- 两组中性粒细胞和血红蛋白水平相当,血小板绝对计数脾切除后持续较高。
核心结论
- 脾切除似乎可减轻接受PRRT的NET患者的白细胞减少并改善血液学耐受性,凸显脾脏在白细胞调控中的作用。
研究设计与样本
- 多中心回顾性研究纳入2009至2022年接受PRRT的68例转移性NET患者,脾切除组34例按年龄、性别、肿瘤部位、分级、转移模式和治疗周期与非脾切除组配对。
主要发现
- 脾切除患者24个月白细胞平均下降12.8%,非脾切除组为47.2%(P<0.001)。
- 脾切除组白细胞中位绝对计数为7.2×10³/mm³,对照组为4.2×10³/mm³(P<0.001)。
- 白细胞减少在脾切除组发生2例,对照组20例(P<0.001)。
- 淋巴细胞下降在脾切除组也较轻,24个月绝对计数更高;血小板计数脾切除后持续较高,但相对变化无统计学意义。
- 中性粒细胞计数和血红蛋白水平两组相当。
关键数值与推荐
- 血液毒性采用不良事件通用术语标准(CTCAE)分级。
- 统计分析采用t检验、Mann-Whitney U检验和Fisher精确检验,α=0.05并应用Bonferroni校正。
临床怎么用
- 脾切除患者可能更好地耐受强化PRRT方案,包括增加周期或再诱导,且毒性最小。
- 该结果对常接受脾切除且预后较差的胰腺NET患者尤其相关。
局限性
- 需前瞻性研究进一步明确脾脏对PRRT相关血液毒性的影响并指导治疗优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is an approved treatment for metastatic neuroendocrine tumors (NETs). Although the therapy is effective, hematologic toxicity, particularly leukopenia, remains a significant concern. The spleen, which accumulates radiolabeled somatostatin analogs, may play a critical role in modulating this toxicity. This study investigates whether patients undergoing PRRT after splenectomy exhibit lower hematologic toxicity. Methods: This multicenter retrospective study included 68 patients with metastatic NETs treated with PRRT between 2009 and 2022. Splenectomized patients (n = 34) were matched to nonsplenectomized patients on the basis of age, sex, tumor location, grading, metastatic pattern, and treatment cycles. Hematologic parameters (leukocytes, lymphocytes, neutrophils, hemoglobin, and platelets) were assessed at baseline and 12 and 24 mo after PRRT. Hematotoxicity was graded using Common Terminology Criteria for Adverse Events. Statistical analyses included t test, Mann-Whitney U test, and Fisher exact test, with an α of 0.05 and Bonferroni adjustment applied. Results: Splenectomized patients had significantly lower rates of leukopenia, with a mean decline of 12.8% in leukocyte count at 24 mo versus 47.2% in nonsplenectomized patients (P < 0.001), and a higher median absolute leukocyte count (7.2 vs. 4.2 × 10³/mm³, P < 0.001). Leukopenia occurred in 2 splenectomized patients compared with 20 in the control group (P < 0.001). Lymphocyte decline was also less pronounced, with higher absolute counts at 24 mo. Platelet counts were consistently higher postsplenectomy, although relative changes over time were not significant. Neutrophil counts and hemoglobin levels remained comparable between groups. Conclusion: Splenectomy appears to reduce leukopenia and improve hematologic tolerability in NET patients undergoing PRRT, highlighting the spleen's role in leukocyte regulation. These patients may better tolerate intensified PRRT regimens, including additional cycles or reinduction, with minimal toxicity. This is particularly relevant for patients with pancreatic NETs, who frequently undergo splenectomy and face a poorer prognosis. Prospective studies are needed to further clarify the spleen's impact on PRRT-related hematotoxicity and guide treatment optimization.
引用
- Steinhelfer L, Jungmann F, Endroes L, et al. Multicentric Matched-Pair Analysis of Long-Term Hematotoxicity of Peptide Receptor Radionuclide Therapy in Patients Postsplenectomy. J Nucl Med. 2025. PMID: 41043998. doi:10.2967/jnumed.125.270190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。